WO2008003103A3 - Novel multivalent immunoglobulins - Google Patents

Novel multivalent immunoglobulins Download PDF

Info

Publication number
WO2008003103A3
WO2008003103A3 PCT/AT2007/000313 AT2007000313W WO2008003103A3 WO 2008003103 A3 WO2008003103 A3 WO 2008003103A3 AT 2007000313 W AT2007000313 W AT 2007000313W WO 2008003103 A3 WO2008003103 A3 WO 2008003103A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
epitope
novel multivalent
surface molecules
cell surface
Prior art date
Application number
PCT/AT2007/000313
Other languages
German (de)
French (fr)
Other versions
WO2008003103A2 (en
Inventor
Florian Ruecker
Gottfried Himmler
Gordana Wozniak-Knopp
Original Assignee
F Star Biotech Forsch & Entw
Florian Ruecker
Gottfried Himmler
Gordana Wozniak-Knopp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Biotech Forsch & Entw, Florian Ruecker, Gottfried Himmler, Gordana Wozniak-Knopp filed Critical F Star Biotech Forsch & Entw
Priority to PL07718518T priority Critical patent/PL2046831T3/en
Priority to JP2009516813A priority patent/JP5924751B2/en
Priority to DK07718518.9T priority patent/DK2046831T3/en
Priority to ES07718518T priority patent/ES2380127T3/en
Priority to EP07718518A priority patent/EP2046831B1/en
Priority to US12/307,578 priority patent/US20100048877A1/en
Priority to AT07718518T priority patent/ATE540056T1/en
Publication of WO2008003103A2 publication Critical patent/WO2008003103A2/en
Publication of WO2008003103A3 publication Critical patent/WO2008003103A3/en
Priority to US15/677,667 priority patent/US11827720B2/en
Priority to US18/521,492 priority patent/US20240150495A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of said immunoglobulin determining binding to an epitope of said cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to said epitope, its use and methods for producing it .
PCT/AT2007/000313 2006-07-05 2007-06-26 Novel multivalent immunoglobulins WO2008003103A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL07718518T PL2046831T3 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
JP2009516813A JP5924751B2 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulin
DK07718518.9T DK2046831T3 (en) 2006-07-05 2007-06-26 New multivalent immunoglobulins
ES07718518T ES2380127T3 (en) 2006-07-05 2007-06-26 New multivalent immunologies
EP07718518A EP2046831B1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
US12/307,578 US20100048877A1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
AT07718518T ATE540056T1 (en) 2006-07-05 2007-06-26 NEW MULTIVALENT IMMUNOGLOBULINS
US15/677,667 US11827720B2 (en) 2006-07-05 2017-08-15 Multivalent immunoglobulins
US18/521,492 US20240150495A1 (en) 2006-07-05 2023-11-28 Novel Multivalent Immunoglobulins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1147/2006 2006-07-05
AT0114706A AT503889B1 (en) 2006-07-05 2006-07-05 MULTIVALENT IMMUNE LOBULINE

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/307,578 A-371-Of-International US20100048877A1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
US15/677,667 Continuation US11827720B2 (en) 2006-07-05 2017-08-15 Multivalent immunoglobulins

Publications (2)

Publication Number Publication Date
WO2008003103A2 WO2008003103A2 (en) 2008-01-10
WO2008003103A3 true WO2008003103A3 (en) 2008-04-17

Family

ID=38720179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2007/000313 WO2008003103A2 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins

Country Status (12)

Country Link
US (3) US20100048877A1 (en)
EP (2) EP2046831B1 (en)
JP (3) JP5924751B2 (en)
CN (3) CN101522712A (en)
AT (2) AT503889B1 (en)
DK (2) DK2046831T3 (en)
ES (2) ES2380127T3 (en)
HU (1) HUE025035T2 (en)
PL (2) PL2046831T3 (en)
PT (2) PT2463302E (en)
SI (2) SI2046831T1 (en)
WO (1) WO2008003103A2 (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101404512B1 (en) * 2005-01-05 2015-01-29 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
ES2565834T3 (en) 2007-06-01 2016-04-07 University Of Maryland, Baltimore Immunoglobulin constant region Fc receptor binding agents
EP3241842B1 (en) * 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
WO2009088805A2 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
AU2009212747B2 (en) * 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
US20120094874A1 (en) * 2009-07-09 2012-04-19 F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H Stabilized immunoglobulin constant domains
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
MX368531B (en) 2010-07-28 2019-10-07 Gliknik Inc Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions.
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
JP2014500879A (en) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Factors and methods for treating diseases correlated with BCMA expression
US9156917B2 (en) 2011-02-11 2015-10-13 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
JP6339015B2 (en) * 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
JP6628966B2 (en) * 2012-06-14 2020-01-15 中外製薬株式会社 Antigen binding molecule containing an altered Fc region
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc Molecules with antigen binding and polyvalent fc gamma receptor binding activity
ES2876009T3 (en) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
TWI707872B (en) 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
JP6764858B2 (en) 2014-08-15 2020-10-07 メルク パテント ゲーエムベーハー SIRP-alpha immunoglobulin fusion protein
CR20170109A (en) 2014-09-26 2017-07-26 Macrogenics Inc BIO-SPECIFIC MONOVALENT DIACUMS THAT ARE ABLE TO JOIN CD19 AND CD3, AND USES OF THE SAME
TW202313697A (en) 2014-11-11 2023-04-01 日商中外製藥股份有限公司 Library of antigen-binding molecules including modified antibody variable region
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP2017536830A (en) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and CD38
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10982008B2 (en) * 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
JP6602875B2 (en) 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Multivalent molecule containing DR5 binding domain
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CN108136010A (en) 2015-10-08 2018-06-08 宏观基因有限公司 For the conjoint therapy for the treatment of cancer
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
TWI758267B (en) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
KR102514317B1 (en) 2016-04-15 2023-03-27 마크로제닉스, 인크. Novel B7-H3-binding molecules, antibody drug conjugates thereof and methods of use thereof
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
IL263542B1 (en) 2016-06-14 2024-06-01 Xencor Inc Bispecific checkpoint inhibitor antibodies
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
RU2764548C2 (en) 2016-08-09 2022-01-18 Кимаб Лимитед Anti-icos antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017342559B2 (en) 2016-10-14 2022-03-24 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
US11155574B2 (en) 2016-12-09 2021-10-26 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
EP3583120B1 (en) 2017-02-17 2022-10-05 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
EP3415527A1 (en) 2017-06-14 2018-12-19 Technische Universität Dresden Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
AU2018312075A1 (en) 2017-07-31 2020-02-20 Osaka University Highly versatile method of presenting cyclic peptide on protein structure
JP2021500857A (en) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Fusion protein containing enzymes for enzyme replacement therapy
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
BR112020011810A2 (en) 2017-12-12 2020-11-17 Macrogenics, Inc. cd16 binding molecule x disease antigen, pharmaceutical composition, use of pharmaceutical composition, and method for treating a disease
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
JP7337079B2 (en) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド Mutant CD3 binding domains and their use in combination therapy for the treatment of disease
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
EP3806885A2 (en) 2018-06-13 2021-04-21 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
GB201811410D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
JP2024504880A (en) 2018-12-24 2024-02-02 サノフイ Pseudo-FAB-based multispecific binding protein
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
GB201905552D0 (en) 2019-04-18 2019-06-05 Kymab Ltd Antagonists
AU2021250186A1 (en) 2020-03-31 2022-12-01 Chugai Seiyaku Kabushiki Kaisha DLL3-targeting multispecific antigen-binding molecules and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
WO2022010798A1 (en) 2020-07-06 2022-01-13 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
GB202017058D0 (en) 2020-10-27 2020-12-09 Kymab Ltd Antibodies and uses thereof
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
GB202101125D0 (en) 2021-01-27 2021-03-10 Kymab Ltd Antibodies and uses thereof
CN117157319A (en) 2021-03-09 2023-12-01 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and CLDN6
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
CA3217220A1 (en) * 2021-04-19 2022-10-27 Janssen Biotech, Inc. Molecules with engineered antibody constant region variants
GB202107372D0 (en) 2021-05-24 2021-07-07 Petmedix Ltd Animal models and therapeutics molecules
GB202209247D0 (en) 2022-06-23 2022-08-10 Petmedix Ltd Animal models and therapeutic molecules
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294654B1 (en) * 1995-01-19 2001-09-25 Inger Sandlie Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2002032925A2 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20020106370A1 (en) * 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1699826A1 (en) * 2005-01-05 2006-09-13 Rüker, Florian Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570027B1 (en) 1984-03-01 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University T cell receptor-specific for antigen polypeptides and related polynucleotides
EP1186660A3 (en) * 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombination technique
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991010722A2 (en) * 1989-12-27 1991-07-25 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
JP3283041B2 (en) * 1990-07-13 2002-05-20 学校法人藤田学園 Artificial antibody
JP3672306B2 (en) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート Heterodimeric receptor library using phagemids
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
DE69334287D1 (en) 1992-09-25 2009-07-09 Avipep Pty Ltd Targeting molecules-binding polypeptides consisting of an IG-like VL domain bound to an IG-like VH domain
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP1130093A1 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP1165757A1 (en) * 1999-03-05 2002-01-02 Maxygen, Inc. Encryption of traits using split gene sequences
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
DK1247095T3 (en) 1999-12-06 2008-12-08 Univ Illinois High affinity TCR proteins and methods
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
JP2003274960A (en) 2000-02-03 2003-09-30 Japan Science & Technology Corp Soluble t cell receptor protein and method for preparing the same
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
WO2001070947A2 (en) 2000-03-20 2001-09-27 Maxygen, Inc. Method for generating recombinant dna molecules in complex mixtures
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
JP2004511430A (en) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
AU2001273559A1 (en) 2000-07-18 2002-01-30 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
AU2001283496A1 (en) * 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
JP2002058479A (en) 2000-08-14 2002-02-26 Canon Inc Method for obtaining comformational recognition amino acid sequence
US20040082508A1 (en) 2000-11-08 2004-04-29 Henry Yue Secreted proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
DK1409646T3 (en) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
EP1281757A1 (en) 2001-07-31 2003-02-05 Direvo Biotech AG Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
DE60203125T2 (en) 2001-08-31 2006-04-06 Avidex Ltd., Abingdon SOLUBLE T CELL RECEPTOR
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
ES2384235T3 (en) 2001-10-22 2012-07-02 The Scripps Research Institute Integrin-directed compounds
US20040043424A1 (en) 2001-11-15 2004-03-04 Baughn Mariah R Immunoglobulin superfamily proteins
EP2075256A2 (en) * 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20040063924A1 (en) 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
US20030157091A1 (en) 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
EP1482984A4 (en) 2002-02-19 2006-12-20 Syntherica Corp Surrogate antibodies and methods of preparation and use thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003213687A1 (en) 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20040097711A1 (en) 2002-03-12 2004-05-20 Henry Yue Immunoglobulin superfamily proteins
EP1394251A1 (en) 2002-08-23 2004-03-03 Direvo Biotech AG Method for the selective randomization of polynucleotides
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
ATE432290T1 (en) 2002-11-09 2009-06-15 Immunocore Ltd T CELL RECEPTOR ßDISPLAYß
JP2006523437A (en) 2002-12-03 2006-10-19 アヴィデックス リミテッド Receptor complex
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005021595A1 (en) 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CA2550551C (en) * 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
EP1765860B1 (en) 2004-05-19 2008-12-10 MediGene Ltd. High affinity ny-eso t cell receptor
DE602005009825D1 (en) 2004-05-19 2008-10-30 Medigene Ltd METHOD FOR IMPROVING T-CELL RECEPTORS
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
KR20070038557A (en) 2004-07-22 2007-04-10 제넨테크, 인크. Her2 antibody composition
JP2008514685A (en) 2004-10-01 2008-05-08 メディジーン リミテッド T cell receptor containing a non-natural disulfide interchain linkage linked to a therapeutic agent
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20080274133A1 (en) 2004-11-18 2008-11-06 Avidex Ltd. Soluble Bifunctional Proteins
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2648849A1 (en) * 2006-04-14 2007-10-25 Trubion Pharmaceuticals, Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
AU2009212747B2 (en) 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20120094874A1 (en) 2009-07-09 2012-04-19 F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H Stabilized immunoglobulin constant domains
US20120010388A1 (en) 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US20140087957A1 (en) 2012-09-25 2014-03-27 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106370A1 (en) * 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
US6294654B1 (en) * 1995-01-19 2001-09-25 Inger Sandlie Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2002032925A2 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1699826A1 (en) * 2005-01-05 2006-09-13 Rüker, Florian Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADACHI MASAAKI ET AL: "Interaction between the antigen and antibody is controlled by the constant domains: Normal mode dynamics of the HEL-HyHEL-10 complex", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 12, no. 10, October 2003 (2003-10-01), pages 2125 - 2131, XP009092337, ISSN: 0961-8368 *
CORTEZ-RETAMOZO V ET AL: "Efficient tumor targeting by single-domain antibody fragments of camels", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 98, no. 3, 20 March 2002 (2002-03-20), pages 456 - 462, XP002248403, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
DK2046831T3 (en) 2012-05-29
US20100048877A1 (en) 2010-02-25
JP2013240338A (en) 2013-12-05
PT2463302E (en) 2015-07-21
ATE540056T1 (en) 2012-01-15
CN110078828A (en) 2019-08-02
SI2463302T1 (en) 2015-08-31
EP2463302A1 (en) 2012-06-13
ES2539593T3 (en) 2015-07-02
ES2380127T3 (en) 2012-05-08
JP6681855B2 (en) 2020-04-15
HUE025035T2 (en) 2016-01-28
US20240150495A1 (en) 2024-05-09
DK2463302T3 (en) 2015-06-15
US20180051095A1 (en) 2018-02-22
AT503889A1 (en) 2008-01-15
EP2046831B1 (en) 2012-01-04
EP2463302B1 (en) 2015-04-01
EP2046831A2 (en) 2009-04-15
PT2046831E (en) 2012-04-24
CN101522712A (en) 2009-09-02
JP5924751B2 (en) 2016-05-25
JP6215603B2 (en) 2017-10-18
JP2009540837A (en) 2009-11-26
PL2463302T3 (en) 2015-08-31
AT503889B1 (en) 2011-12-15
CN110041430A (en) 2019-07-23
WO2008003103A2 (en) 2008-01-10
US11827720B2 (en) 2023-11-28
JP2017163998A (en) 2017-09-21
PL2046831T3 (en) 2012-06-29
SI2046831T1 (en) 2012-03-30

Similar Documents

Publication Publication Date Title
WO2008003103A3 (en) Novel multivalent immunoglobulins
WO2020041541A3 (en) Anti-tigit antibodies
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2009070243A3 (en) Wise binding antibodies and epitopes
IL184103A0 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2009058492A3 (en) Fc variants with altered binding to fcrn
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2008121616A3 (en) Antibodies with decreased deamidation profiles
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008047134A3 (en) Antibody molecules which bind il-17a and il-17f
WO2009131702A3 (en) Antibodies against fcrn and use thereof
WO2006121422A8 (en) Antibodies against clostridium difficile toxins and uses thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2007095338A3 (en) Functional antibodies
WO2008076379A8 (en) Human antibodies to human delta like ligand 4
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
EP2233501A4 (en) Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
WO2006135527A3 (en) Methods for the selection of aptamers
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2008065384A3 (en) Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
EP2149582A4 (en) Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780032991.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07718518

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009516813

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 7210/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007718518

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12307578

Country of ref document: US